share on Facebook
By Mary Vanac | Cleveland Business Journal
Cleveland Diagnostics Inc. raised $ 19.4 million to help commercialize its first diagnostic test to detect early-stage prostate cancer.
The clinical-stage biotechnology company, which develops diagnostic tests for the early detection of cancer, has completed a Series D round of $ 17.4 million, the company said in a statement.
LYFE Capital led the investment round which included existing investors including the Cleveland Clinic.
Read the full story on cleveland.com’s sister site, the Cleveland Business Journal.
Get the best local business news straight to your inbox with the Cleveland Business Journal. Register for free.
Note to readers: If you buy something through one of our affiliate links, we may receive a commission.